{
    "code": "60001118",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60001118",
    "time": "2021-09-24 03:54:05",
    "許可證字號": "衛部菌疫輸字第001118號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "113\/12\/30",
    "發證日期": "108\/12\/30",
    "許可證種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA06000111807",
    "中文品名": "洛希隆注射劑",
    "英文品名": "Rixathon Concentrate for Solution for Infusion",
    "適應症": "1、非何杰金氏淋巴瘤\r\n(1)用於復發或對化學療法有抗性之低惡度B-細胞非何杰金氏淋巴瘤。\r\n(2)併用CVP化學療法用於未經治療之和緩性(組織型態為濾泡型)B細胞非何杰金氏淋巴瘤的病人。\r\n(3)併用CHOP或其他化學療法用於CD20抗原陽性之瀰漫性大型B細胞非何杰金氏淋巴瘤。 \r\n(4)用於做為濾泡性淋巴瘤病人對誘導療法產生反應之後的維持治療用藥。\r\n2、慢性淋巴球性白血病\r\n(1)適用於與fludarabine及cyclophosphamide併用，做為CD20陽性慢性淋巴球性白血病(CLL)病人的第一線用藥。 \r\n(2)適用於與化學療法併用，做為復發\/頑固性的CD20陽性慢性淋巴球性白血病病人的治療用藥。\r\n3、肉芽腫性血管炎(Granulomatosis with Polyangiitis, GPA)(Wegener’s肉芽腫症)及顯微多發性血管炎(Microscopic Polyangiitis, MPA)：與葡萄糖皮質素(glucocorticoids)併用，適用於治療成人之肉芽腫性血管炎(GPA，亦稱為韋格納肉芽腫症)及顯微多發性血管炎(MPA)。",
    "劑型": "27D注射液劑",
    "包裝": "10毫升、50毫升玻璃小瓶裝，100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "113\/12\/30",
    "主成分略述": "Rituximab",
    "限制項目": "02輸　入 1D須執行風險管理計畫 91生物相似性藥品",
    "申請商名稱": "0924601100  台灣諾華股份有限公司",
    "申請商地址": "台北市中山區民生東路三段2號8樓",
    "主製造廠": [
        {
            "製造廠名稱": "FSI0004000  LEK PHARMACEUTICALS D.D., SLOVENIA",
            "製造廠廠址": "VEROVSKOVA 57, SI-1526 LJUBLJANA, SLOVENIA",
            "製造廠公司地址": "",
            "製造廠國別": "SLOVENIA",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "FAT0030000  SANDOZ GMBH,  SCHAFTENAU PLANT",
            "製造廠廠址": "BIOCHEMIESTRASSE 10, 6336 SCHAFTENAU\/LANGKAMPFEN, AUSTRIA",
            "製造廠公司地址": "",
            "製造廠國別": "AUSTRIA",
            "製程": "原料藥製造廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013002400",
            "成分名稱": "Rituximab",
            "含量描述": "",
            "含量": "10.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "Rixathon_TWI-030320 into TWI-020321_Clear ver-110-08-30.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001118&Seq=003&Type=9"
        },
        {
            "title": "Rixathon 500mg50ml_LB_man-v2-109-03-16.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001118&Seq=006&Type=8"
        },
        {
            "title": "Rixathon 500mg50ml_FB_man-v2-109-03-16.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001118&Seq=005&Type=8"
        },
        {
            "title": "Rixathon 500mg50ml_FB_mac-v10-109-03-16.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001118&Seq=004&Type=8"
        },
        {
            "title": "Rixathon 100mg10ml_LB_mac-v10-109-03-16.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001118&Seq=003&Type=8"
        },
        {
            "title": "Rixathon 100mg10ml_FB_man-v2-109-03-16.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001118&Seq=002&Type=8"
        },
        {
            "title": "Rixathon 100mg10ml_FB_mac-v10-109-03-16.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001118&Seq=001&Type=8"
        }
    ]
}